BioSpace News Archive

A small study by researchers in Israel published in the journal Rheumatology identified six cases of patients developing herpes zoster rashes (shingles) after receiving the Pfizer-BioNTech vaccine.

Six months after bagging $115 million in a Series B financing round, Talaris Therapeutics is aiming to raise another $100 million through in initial public offering. It’s one of three companies joining in the flurry of IPOs this week.

Recursion Pharmaceuticals, Inc. (“Recursion” or “we”) announced the closing on April 20, 2021 of its initial public offering of 27,878,787 shares of its Class A common stock, which includes the exercise in full of the underwriters’ option to purchase 3,636,363 additional shares of its Class A common stock, at a price to the public of $18.00 per share.

Evofem Biosciences, Inc., (NASDAQ: EVFM) today announced the company will deliver the keynote address and present two poster presentations on Phexxi® (lactic acid, citric acid, potassium bitartrate) at the upcoming NCODA 2021 National Spring Forum, which will be held April 28 to 30 as a virtual E-Meeting.

SimonMed Imaging, one of the largest independent outpatient medical imaging providers and physician radiology practices in the United States, and American Securities LLC, a leading U.S. private equity firm, announced a strategic partnership that includes an investment from American Securities to support continued growth.

ATCC, the world’s premier biological materials management and standards organization, today announced that five high-quality, concentrated virus preparations that it produced and stored under contract from the U.S. Food and Drug Administration’s Center for Biologics Evaluation and Research (FDA/CBER)

Apollo Medical Holdings, Inc. (“ApolloMed,” and together with its subsidiaries and affiliated entities, the “Company”) (NASDAQ: AMEH), a leading physician-centric, technology-powered healthcare management company, today announced that it will release financial results for the first quarter ended March 31, 2021, after the close of the stock market on Wednesday, May 5, 2021

Baxter International Inc. (NYSE:BAX), a global leader in acute care, today announced it received a new research and development (R&D) grant from the German Federal Ministry of Education and Research (BMBF).

Mercy Health Urogynecology, has enrolled their first patient in the VESAIR Clinical Trial. The VESAIR Clinical Trial is being conducted in several distinguished clinics throughout the US to test the safety and efficacy of the Vesair Bladder Control Balloon procedure.

ProHEALTHcare Garden City Urology, has enrolled their first patient in the VESAIR Clinical Trial